We are delighted to announce that we just launched our first version of the Mobile Application & Web Portal to all our active customers as a significant step to execute our B2B part of Digital strategy.
This step coming as one of the most important steps we took to interact and support the market with the latest updated technologies adapted with the Digital Transformation Era .
Ibnsina Pharma expands business with Mundipharma by signing an importation and distribution partnership. The strong relationship between the two companies resulted in adding Mundipharma imported products to ibnsina Pharma portfolio.
Cairo, 28 November 2019…
Ibnsina Pharma (ISPH.CA on the Egyptian Stock Exchange), Egypt’s fastest-growing and second-largest pharmaceutical distributor, has signed an agreement with Mundipharma in Egypt, a global pioneer in pharmaceuticals and diagnostics, to import and distribute Mundipharma imported products in Egypt. The strong relationship between the two companies resulted in expanding business to see Ibnsina Pharma adding Mundipharma’s imported products beside Mudipharma’s local products which ibnsina Pharma already distribute in Egypt. Mundi pharma products covers six therapeutic areas; pain, oncology, respiratory, ophthalmology, specialty care and consumer health supporting over 4 billion patients across the globe.
“We are excited to have partnered with Mundipharma, a multinational company with a visionary approach and innovative spirit that improve the health and well-being of people around the world. This strategic partnership will allow Ibnsina Pharma to not only further strengthen its product offering but will give patients across Egypt unprecedented access to the latest pharmaceutical treatments available,” said Mohsen Mahgoub, Chairman of Ibnsina Pharma. “Expanding business with Mundipharma Egypt is a testament to the success of our business model, which provides our partners with distribution, importation, storage and value-added marketing services and has allowed us to become the distributor of choice for both foreign and domestic suppliers. The agreement capitalizes on Ibnsina’s wide distribution network. We expect to generate around 120 million EGP in sales from all Mundipharma’s products by end of 2020,” said Mahgoub.
Mundipharma Egypt aims for expanding its network of partners that offers the best support to patients to be able to access their innovative therapies and expand their coverage all over Egypt. Ibnsina Pharma has over 350 international and domestic suppliers who trust Ibnsina Pharma to distribute their products to over 42,000 pharmacies, retail chains,wholesalers and healthcare institutions across Egypt’s governorates.
“Mundipharma aims to improve the lives of those who need our medicine the most, enabling everyone to live better. Mundipharma have 38 products across six therapeutic areas with a distribution network covering six continents through 8 manufacturing sites. We are feeling optimistic to sign this distribution agreement with Ibnsina Pharma, trusting the high-efficiency, and the level of services offered to support our patients throughout Egypt. I look forward to growing our partnership, offering patients in Egypt access to the latest innovations” said Dr. Ashraf Allam, Vice President Mundipharma Middle East, Africa, Turkey at Mundipharma.
Ibnsina Pharma signed an importation and distribution partnership with Roche Egypt LLC which will see IbnsinaPharma distribute all 40 Roche SKUs throughout Egypt. Roche 40 SKU’s recorded EGP 1.435 billion in sales in FY2018 in Egypt.
Cairo, 2 September 2019,
Ibnsina Pharma (ISPH.CA on the Egyptian Stock Exchange), Egypt’s fastest-growing and second-largest pharmaceutical distributor, has signed an agreement with Roche pharmaceuticals in Egypt, the world’s largest biotech company and global pioneer in pharmaceuticals and diagnostics, to import and distribute Roche products in Egypt. The agreement will see Ibnsina Pharma distribute all 40 high-tech SKUs expected to bring significant benefits to patients suffering from diseases such as cancer, multiple sclerosis and hemophilia.
“We are excited to have partnered with Roche, a multinational company with a long-standing reputation in the provision
of innovative pharmaceutical solutions that improve the health and well-being of people around the world. This strategic
partnership will allow Ibnsina Pharma to not only further strengthen its product offering but will give patients across Egypt
unprecedented access to the latest pharmaceutical treatments available,” said Mohsen Mahgoub , Chairman of Ibnsina
Pharma. “Being selected as a distributor for Roche products in Egypt is a testament to the success of our one-stop shop
model, which provides our partners with distribution, importation, storage and value-added marketing services and has
allowed us to become the distributor of choice for both foreign and domestic suppliers. As part of this partnership, Ibnsina
and Roche will collaborate to the fullest extent to offer Egyptian patients world-class standards of quality. The agreement
also capitalizes on Ibnsina’s cold-chain capacity. Capitalizing on our distribution network, no initial investments needed.
We expect to generate around EGP 300 million in sales by end of 2020,” said Mahgoub.
Roche Egypt LLC, which is currently partnering with one public-sector and other private distribution company, aims for expanding its network of partners that offers the best support to patients to be able to access their innovative therapies and expand their coverage all over Egypt. Ibnsina Pharma has over 350 international and domestic suppliers who trust Ibnsina Pharma to distribute their products to over 42,000 pharmacies, retail chains, wholesalers and healthcare institutions across Egypt’s governorates. Roche recorded EGP 1.435 billion in sales in FY2018 in Egypt, according to IMS — commanding a market share of 1.6%.
“Roche aims to improve patient access to medical innovations by working with all relevant stakeholders and in partnership with others, together we spark meaningful change for the future of human health. This is why we work together with partners – academia, governments, startups – across the entire value chain from early research to patient access. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarial and cancer medicines and we are feeling optimistic
to sign this distribution agreement with Ibnsina Pharma, trusting the high-efficiency, and the level of services offered to support our patients throughout Egypt. Roche is committed to reach and help as many patients as possible so it was important for us to find local partners whose values and their strategic vision are aligned with our own, and this is a cornerstone for our collaboration with Ibnsina Pharma. I look forward to growing our partnership together for years to come, offering patients in Egypt access to the latest innovations” said Roche Egypt Country Manager, Mohamed Swilam.
About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalized healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to
search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The
company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the tenth consecutive year, Roche has been recognized as the most sustainable company in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices
(DJSI). The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2018 employed about 94,000 people worldwide. In 2018, Roche invested CHF 11 billion in R&D and posted sales of CHF 56.8 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.
About Ibnsina Pharma
Originally established in 2001, today Ibnsina Pharma is Egypt’s fastest-growing and second largest pharmaceutical distribution company. The Company distributes a competitive portfolio of pharmaceutical products from over 350 multinational and Egyptian pharmaceutical companies to more than 42,000 customers including pharmacies, hospitals, retail outlets and wholesalers. Its fleet of around 670 vehicles completes an average of over 460,000 deliveries each month.
Ibnsina Pharma’s core services for suppliers include management of warehousing and logistics for pharmaceutical products as well as the development and execution of tailored marketing solutions targeting a nationwide database of customers. The Company also provides efficient and reliable order-taking and delivery services to customers and was the first in its industry to pioneer a telesales model. Operating across 62 sites nationwide, Ibnsina Pharma’s team of more than 6,000 employees is dedicated to improving people’s quality of life by ensuring their access to safe and high-quality pharmaceutical products.
All trademarks used or mentioned in this release are protected by law.
Acknowledging the Company’s strong performance in 2018 and its ongoing commitment to deliver a competitive portfolio of goods & reliable services, Ibnsina Pharma is among the top 100 companies honored at this year’s awards ceremony held by Amwal Al Ghad Magazine
Cairo, 23 January 2019
Ibnsina Pharma (ISPH.CA on the Egyptian Stock Exchange), Egypt’s fastest-growing and second-largest pharmaceutical distributor, was recognized as one of the “Top 100 Companies” in Egypt in 2018 by Amwal Al Ghad Magazine, a leading business and economics magazine in Egypt and the Middle East.
Amwal Al Ghad Awards seek out the leading lights of the business industry, looking for those whose creativity, commitment, experience and strong leadership has helped them achieve success in an increasingly challenging corporate climate. Ibnsina Pharma continued success and ability to grow faster than peers and consistently outperform the market came through the careful execution of a value-based differentiation strategy. A strategy that is built on information and the continued investment in market intelligence, research and an understanding of clients’ needs.
“It’s a great honor to be recognized with Amwal Al Ghad Award”, said Mahmoud Abdel Gawad, CO-CEO Ibnsina Pharma. “This is an acknowledgment of all the talented and committed people whom I have been fortunate enough to work with over the past few years”.
“Performance awards is what all organizations aspire to. This award is a testament to ibnsina Pharma incredible growth, our passionate team who deliver sustainable value creation and high quality service to our stakeholders” said Omar Abdel Gawad, CO-CEO Ibnsina Pharma.
The award was presented at Amwal Al Ghad’s fourth annual awards ceremony held on 21 January 2018 with ministers, high profile officials, CEOs, business leaders and heads of public and private institutions in Egypt in attendance, under the auspices of H.E. the prime minister Dr.Mostafa Madbouly who delegated Mr.Hisham Tawfik Minister of Public Enterprise in attending the event and handing out the awards.
About Ibnsina Pharma
Originally established in 2001, today Ibnsina Pharma is Egypt’s fastest-growing and second largest pharmaceutical distribution company. The Company distributes a competitive portfolio of pharmaceutical products from over 350 Egyptian and multinational pharmaceutical companies to more than 42,000 customers including pharmacies, hospitals, retail outlets and wholesalers. Its fleet of around 650 vehicles completes an average of over 460,000 deliveries each month.
Ibnsina Pharma’s core services for suppliers include management of warehousing and logistics for pharmaceutical products as well as the development and execution of tailored marketing solutions targeting a nationwide database of customers. The Company also provides efficient and reliable order-taking and delivery services to customers and was the first in its industry to pioneer a telesales model. Operating across 59 sites in 23 cities nationwide, Ibnsina Pharma’s team of more than 5,500 employees is dedicated to improving people’s quality of life by ensuring their access to safe and high quality pharmaceutical products.
The companies signed two contracts authorizing Ibnsina Pharma to distribute 20+ stock-keeping units of life-saving diabetes care and other Novo Nordisk’s products in Egypt and establishing a partnership between the two companies.
20 March 2018 | Cairo, Egypt
Ibnsina Pharma (ISPH.CA on the Egyptian Stock Exchange), Egypt’s fastest-growing and second-largest pharmaceutical distributor, has signed two contacts with Novo Nordisk, leading manufacturer of insulin and haemophilia treatment , to distribute over 20 stock-keeping units of its diabetes care , haemophilia and growth disorders products in Egypt.
Previously reliant on one public-sector distribution company and one private distribution company, Novo Nordisk will join a group of over 325 domestic and international suppliers who rely on Ibnsina Pharma to distribute their products to over 39,000 pharmacies, retail chains, wholesalers, public and private hospitals across Egypt.
“We are incredibly proud and excited by this new opportunity to distribute Novo Nordisk’s life-saving diabetes care, haemophilia and growth disorders products across Egypt,” said Mohsen Mahgoub, Chairman of Ibnsina Pharma. “Our primary objective is leveraging our distribution network to provide much-needed access to medication, and diabetes care products which are essential drugs in Egypt. At Ibnsina Pharma, our commitment to maintaining high operating standards and serving as a one-stop shop providing storage, distribution and value-added marketing services has allowed us to become highly successful in the market and a distributor of choice for many suppliers from both Egypt and abroad.”
In preparation for distributing this new array of medical products, Ibnsina Pharma invested EGP 2 million in additional warehousing facilities and allocated 28 specialized trucks to deliver Novo Nordisk’s cold-chain products. Currently the company has a total of 55 operational sites across the country. As part of the conditions to attain these new contracts Ibnsina Pharma also passed Novo Nordisk’s due diligence and operational audit to meet international standards.
“Our investment to accommodate these contracts is the first execution in our plan to invest EGP 700 million in new sites and expansion of Ibnsina Pharma’s network over the next five years. This expansion is made possible by our successful IPO, conducted in the fourth quarter of 2017 which was c. 18 times oversubscribed. Adding Novo Nordisk’s high-demand products to our portfolio will continue to drive our profits and feed into our long-term plan for growth, Mahgoub asserted.”
8 November 2017 | Cairo, Egypt
Ibnsina Pharma S.A.E. (“Ibnsina” or the “Company”), Egypt’s fastest-growing and second-largest distributor of pharmaceutical products, finalized today the listing of its shares on the Egyptian Exchange (EGX).
The listing comes in advance of Ibnsina’s planned initial public offering on the EGX (the “Offering”). The Offering is expected to consist of a primary offering of newly issued shares and a secondary offering of existing shares held by the Company’s current shareholders (collectively the “Shares”) constituting around 37.5% of Company’s total share capital post-money.
Proceeds from the transaction will be used to grow Ibnsina’s core distribution business and support its expansion into new, higher-margin revenue streams.
“I am very pleased that we have finalized the listing procedures, an important regulatory milestone for our transaction. We have also concluded our pre-marketing roadshow and have recorded strong interest from investors in London, Frankfurt, the United Arab Emirates, Saudi Arabia, South Africa, and the United States, and look forward to our deal roadshow during the second half of November,” said Mohsen Mahgoub, Executive Chairman of Ibnsina.
Separately, the Company confirmed that Pharos, acting as independent financial advisor (“IFA”), has completed its fair value report on Ibnsina’s shares. Ibnsina has submitted the IFA report to Egypt’s Financial Regulatory Authority (FRA) for review and approval.
The Offering is expected to take place in December, subject to market conditions and the receipt of regulatory approvals.
Ibnsina is Egypt’s fastest-growing and second-largest pharmaceutical distributor serving over 35,000 clients including retail pharmacies, wholesalers, hospitals and public health institutions across Egypt with products from over 325 local and multinational pharmaceutical companies. Ibnsina Pharma has a market share of c.18.8% 1 and expects to close 2017 with revenues in excess of EGP 9.5bn. Established in 2001, the Company has been the fastest -growing pharmaceutical distributor in Egypt, with revenues growing at a CAGR of 30% over the past five years compared to an industry CAGR of c.17%.
The Company has over 5,500 employees and a fleet of around 600 vehicles serving nationwide demand through a network of 55 operational sites2 including warehouses and distribution hubs, among others, and has over 850 telesales personnel.
Ibnsina’s growth prospects are buoyed by favorable market conditions as well as recent regulatory reforms allowing pharmaceutical manufacturers to re-price their products.
The European Bank for Reconstruction and Development is a minority shareholder of Ibnsina, having acquired a 21% stake through primary and secondary share transactions in 2015.
The Company’s other shareholders include the Mahgoub family (24%), the Abdel Gawad family (22%), and Faisal Islamic Bank (16%). Other shareholders, including members of the senior management team, collectively hold the remaining 17%.
Beltone Investment Banking is acting as Sole Global Coordinator and Bookrunner on the Offering, while Matouk Bassiouny is acting as counsel to the issuer.
About Ibnsina Pharma
Originally established in 2001, today Ibnsina Pharma is Egypt’s fastest-growing and second largest pharmaceutical distribution company. The Company distributes a competitive portfolio of pharmaceutical products from over 325 local and multinational pharmaceutical companies to over 35,000 customers including retail pharmacies, wholesalers, hospitals, and public health institutions. Its fleet of around 600 vehicles completes an average of over 375,000 deliveries each month.
Ibnsina’s core services for suppliers include management of warehousing and logistics for pharmaceutical products as well as the development and execution of tailored marketing solutions targeting a nationwide database of customers. The Company also provides efficient and reliable order-taking and delivery services to customers and was the first in its industry to pioneer a telesales model. Operating across 55 sites in 23 governorates nationwide by end of 2017, Ibnsina’s team of more than 5,500 employees is dedicated to improving people’s quality of life by ensuring their access to safe and high quality pharmaceutical products.
For more information about Ibnsina Pharma, please visit: www.ibnsina-pharma.com.
About Beltone Financial Holding
Beltone Financial is a leading regional investment bank, offering a full range of financial services to companies, institutions and high- net-worth individuals in the Middle East, Europe, North America, and Asia. Beltone is the largest asset manager in Egypt with c. EGP 25 bn in AuM and a leading provider of independent equity research in the region. The firm’s track record includes the execution of over EGP 100 bn in M&A and capital markets transactions. Beltone is present on ground in the US through its subsidiary Auerbach Grayson, a New York-based brokerage and placement agent with access to over 125 markets globally. In 2015, the firm was acquired by Orascom Telecom Media & Technology (OTMT). Beltone is listed on the Egyptian Exchange trading under BTFH.CA.
Disclaimer
The Company and Beltone Investment Banking, S.A.E. (“Beltone”) do not make any representation or warranty, express or implied, as to the accuracy or completeness of the information contained in this announcement, including the suitability of the Shares for any particular investor, and nothing contained in this Announcement is, or should be relied upon as, a promise or representation by the Company or Beltone or their respective affiliates or advisors. This Announcement does not constitute, or form part of, any offer or invitation to sell, allot or issue, or any solicitation of any offer to purchase or subscribe for, any securities, nor shall it (or any part of it) or the fact of issue by the Company form the basis of, or be relied upon in connection with, or act as any inducement to enter into, any contract or commitment for securities. Any purchase or subscription for Shares pursuant to the Offering must be made only on the basis of the information contained in the offering prospectus or the public subscription notice (the “PSN”). As this announcement is intended for advertising purposes, no reliance may be placed for any purpose whatsoever on the information or opinions contained in this announcement or on its completeness, accuracy or fairness. No undertaking, representation, warranty or other assurance, express or implied, is made or given by or on behalf of the Company nor directors, officers, employees, agents or advisers or any other person as to the accuracy or completeness or fairness of the information or opinions contained in this Announcement and no responsibility or liability is accepted by them for any such information or opinions.
Persons reviewing this Announcement should note that it has not been independently verified and that Beltone is acting for the Company in relation to the Offering and for no one else and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients or for providing advice in relation to the Offering or the contents of this Announcement or any transaction, arrangement or matter referred to herein.
The distribution of this announcement and other information in connection with the Offering, may be restricted by law in certain jurisdictions, and persons into whose possession this announcement or any document or other information referred to herein comes should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.
In particular, this Announcement is not for distribution or being made available in or into the United States, Canada, Australia, Qatar, the Republic of Ireland, Kuwait, the Republic of South Africa or Japan or to any US persons (“US Persons”) as defined in Regulation S (“Regulation S”) under the US Securities Act of 1933, as amended (the “US Securities Act”). The Shares have not been registered under the US Securities Act, or under the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States, or to, or for the account or benefit of, US Persons except in a manner fully compliant with the US Securities Act. The Shares have not been and will not be registered under the securities laws of Canada, Australia, Qatar, the Republic of Ireland, Kuwait, the Republic of South Africa or Japan. Accordingly, the Shares may not, subject to certain exceptions, be offered or sold, directly or indirectly in or into Canada, Australia, Qatar, the Republic of Ireland, Kuwait, the Republic of South Africa or Japan or to any national, citizen or resident of Canada, Australia, Qatar, the Republic of Ireland, Kuwait, the Republic of South Africa or Japan.
No person has been authorized to give any information or make any representations other than those contained in the PSN and, if given or made, such information or representations must not be relied upon as having been so authorized by the Company. The Company will comply with its legal obligation (if any) to publish a supplementary announcement containing further updated information if so required by law or by any regulatory authority but assumes no further obligation to publish additional information.
Forward-looking Statements
Certain statements in this announcement are not historical facts and are forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s control and all of which are based on the Company’s current beliefs and expectations in relation to future events. The forward-looking statements are typically identified by the use of forward-looking terminology, such as “believes”, “expects”, “may”, “will”, “could”, “would”, “should”, “intends”, “targets”, “aims”, “projects”, “estimates”, “plans”, “assumes”, “potentially” or “anticipates” or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy that involve risks and uncertainties. In addition, from time to time, representatives of the Company have made or may make forward- looking statements orally or in writing. Furthermore, such forward-looking statements may be included in, but are not limited to, press releases or oral statements made by, or with the approval of, an authorized executive officer of the Company. Forward-looking statements include statements concerning the Company’s plans, objectives, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs, plans or intentions relating to acquisitions, competitive strengths and weaknesses, business strategy and the trends anticipated in the industries and the political and legal environment in which the Company operates and other information that is not historical information. These forward-looking statements and other statements contained in this Announcement regarding matters that are not historical facts involve predictions. No assurance can be given that such future results will be achieved; actual events or results may differ materially as a result of risks and uncertainties facing the Company. Such risks and uncertainties could cause actual results to vary materially from the future results indicated, expressed or implied in such forward-looking statements. Prospective investors should be aware that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in such forward-looking statements. When relying on forward-looking statements, prospective investors should carefully consider uncertainties and events. Such forward-looking statements speak only as of the date on which they are made. Accordingly, the Company does not undertake any obligation to update or revise any of them, whether as a result of new information, future events or otherwise other than as required by applicable laws or regulation. The Company does not make any representation, warranty or prediction that the results anticipated by such forward-looking statements will be achieved, and such forward-looking statements represent, in each case, only one of many possible scenarios and should not be viewed as the most likely or standard scenario. Neither the Company nor Beltone may give any assurance or accept any liability for the accuracy of the opinions set forth herein or as to the actual occurrence of any predicted developments. Accordingly, prospective investors should not rely on the forward-looking statements in this Announcement and must read the PSN in its entirety.
Beltone Investment Banking is acting as sole global coordinator and bookrunner to Egypt’s fastest-growing pharmaceutical distributor
18 September 2017 | Cairo, Egypt
Ibnsina Pharma S.A.E. (“Ibnsina” or the “Company”), Egypt’s fastest-growing and second largest distributor of pharmaceutical products, announced today its intention to proceed with an initial public offering on the Egyptian Exchange (the “Offering”). The Offering is expected to consist of a primary Offering of newly issued shares and a secondary Offering of existing shares held by the Company’s
current shareholders (collectively the “Shares”) constituting around 25% of Ibnsina Pharma’s total
shares.
Proceeds from the transaction will be used to grow Ibnsina’s core distribution business and support its expansion into new, higher-margin revenue streams.
The Offering is expected to take place in late Q4 2017 or early Q1 2018, subject to market conditions and the receipt of regulatory approvals.
Mohsen Mahgoub, Chairman of Ibnsina, said: “We are very pleased to be taking the first steps in our journey to becoming a publicly traded company. Today, we are Egypt’s fastest-growing and second largest pharmaceutical distributor serving around 34,000 clients including retail pharmacies, hospitals and public health units across Egypt with products from over 300 local and multinational
pharmaceutical companies. We have grown from a standing start in 2001 through careful execution of what we call our value-based differentiation strategy, which has allowed us to grow substantially faster than others in our market. As we have done so, our core team — the majority of whom have been with us for 15 or more years, and many of whom are shareholders themselves — have become
experts in managing complexity: Delivering every day on a high volume of transactions for a large number of suppliers and an even larger number of end consumers.
Ibnsina Pharma is Egypt’s second-largest pharmaceutical distributor with a market share of c.18.5%1 and 2017 revenues expected to exceed EGP 9.5bn. Established in 2001, the Company has been the fastest-growing pharmaceutical distributor in Egypt, with revenues growing at a CAGR of 30% over the past five years compared to an industry CAGR of c.17%.
The Company has over 5,500 employees and a fleet of around 600 vehicles serving nationwide demand through a network of 55 operational sites including warehouses and distribution hubs, among others, and has over 850 telesales personnel.
Ibnsina expects to post significant growth in 2017 based on favorable market conditions and recent regulatory reforms allowing pharmaceutical manufacturers to re-price their products.
The European Bank for Reconstruction and Development (“EBRD”) is a minority shareholder of Ibnsina, having acquired a 21% stake through primary and secondary share transactions in 2015.
Mahgoub added on the announcement “The presence of institutional shareholders such as EBRD and Faisal Islamic Bank has allowed us to significantly enhance our corporate governance practices and systems ahead of our intended listing on the Egyptian Exchange. This experience has prepared Ibnsina for this next step, as we have built a platform that is capable of continuously creating value for
all our shareholders.”
The Company’s shareholders include the Mahgoub family (24%), the Abdel Gawad family (23%), EBRD (21%), and Faisal Islamic Bank (16%). Other shareholders, including members of the senior management team, collectively hold the remaining 16%.
Beltone Investment Banking is acting as Sole Global Coordinator and Bookrunner on the Offering, while Matouk Bassiouny is acting as counsel to the issuer.
About Ibnsina Pharma
Originally established in 2001, today Ibnsina Pharma is Egypt’s fastest-growing and second largest pharmaceutical distribution company. The Company distributes a competitive portfolio of pharmaceutical products from over 300 Egyptian and multinational pharmaceutical companies to more than 34,000 customers including pharmacies, hospitals, retail outlets and wholesalers. Its fleet
of around 600 vehicles completes an average of over 375,000 deliveries each month. Ibnsina’s core services for suppliers include management of warehousing and logistics for pharmaceutical products as well as the development and execution of tailored marketing solutions targeting a nationwide database of customers. The Company also provides efficient and reliable
order-taking and delivery services to customers and was the first in its industry to pioneer a telesales
model. Operating across 55 sites in 23 cities nationwide, Ibnsina’s team of more than 5,500 employees is dedicated to improving people’s quality of life by ensuring their access to safe and high quality pharmaceutical products.
For more information about Ibnsina Pharma, please visit: www.ibnsina-pharma.com.
About Beltone Financial Holding
Beltone Financial is a leading regional investment bank, offering a full range of financial services to companies, institutions and high-net-worth individuals in the Middle East, Europe, North America, and Asia. Beltone is the largest asset manager in Egypt with c. EGP 25 bn in AuM and a leading provider of independent equity research in the region. The firm’s track record includes the execution of over EGP 100 bn in M&A and capital markets transactions. Beltone is present on ground in the US through its subsidiary Auerbach Grayson, a New York-based brokerage and placement agent with access to over 125 markets globally. In 2015, the firm was acquired by Orascom Telecom Media & Technology(OTMT). Beltone is listed on the Egyptian Exchange trading under BTFH.CA.
Disclaimer
The Company and Beltone Investment Banking, S.A.E. (“Beltone”) do not make any representation or warranty, express or implied, as to the
accuracy or completeness of the information contained in this announcement, including the suitability of the Shares for any particular investor, and nothing contained in this Announcement is, or should be relied upon as, a promise or representation by the Company or Beltone or their respective affiliates or advisors. This Announcement does not constitute, or form part of, any offer or invitation to sell, allot or issue, or any solicitation of any offer to purchase or subscribe for, any securities, nor shall it (or any part of it) or the fact of issue by the Company form the basis of, or be relied upon in connection with, or act as any inducement to enter into, any contract or commitment for securities. Any purchase or subscription for Shares pursuant to the Offering must be made only on the basis of the information contained in the offering prospectus or the public subscription notice (the “PSN”). As this announcement is intended for advertising purposes, no reliance may be placed for any purpose whatsoever on the information or opinions contained in this announcement or on its completeness, accuracy or fairness. No undertaking,representation, warranty or other assurance, express or implied, is made or given by or on behalf of the Company nor directors, officers, employees, agents or advisers or any other person as to the accuracy or completeness or fairness of the information or opinions contained in this Announcement and no responsibility or liability is accepted by them for any such information or opinions.
Persons reviewing this Announcement should note that it has not been independently verified and that Beltone is acting for the Company inrelation to the Offering and for no one else and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients or for providing advice in relation to the Offering or the contents of this Announcement or any transaction, arrangement or matter referred to herein.
The distribution of this announcement and other information in connection with the Offering, may be restricted by law in certain jurisdictions, and persons into whose possession this announcement or any document or other information referred to herein comes should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.
In particular, this Announcement is not for distribution or being made available in or into the United States, Canada, Australia, Qatar, the Republic of Ireland, Kuwait, the Republic of South Africa or Japan or to any US persons (“US Persons”) as defined in Regulation S (“Regulation S”) under the US Securities Act of 1933, as amended (the “US Securities Act”). The Shares have not been registered under the US Securities Act, or under the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States, or to, or for the account or benefit of, US Persons except in a manner fully compliant with the US Securities Act. The Shares have not been and will not be registered under the securities laws of Canada, Australia, Qatar, the Republic of Ireland, Kuwait, the Republic of South Africa or Japan.
Accordingly, the Shares may not, subject to certain exceptions, be offered or sold, directly or indirectly in or into Canada, Australia, Qatar, the Republic of Ireland, Kuwait, the Republic of South Africa or Japan or to any national, citizen or resident of Canada, Australia, Qatar, the Republic
of Ireland, Kuwait, the Republic of South Africa or Japan.
No person has been authorized to give any information or make any representations other than those contained in the PSN and, if given or made, such information or representations must not be relied upon as having been so authorized by the Company. The Company will comply with its legal obligation (if any) to publish a supplementary announcement containing further updated information if so required by law or by anyregulatory authority but assumes no further obligation to publish additional information.
Forward-looking Statements Certain statements in this announcement are not historical facts and are forward-looking statements.
These forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s control and all of which are based on the Company’s
current beliefs and expectations in relation to future events. The forward-looking statements are typically identified by the use of forward-looking terminology, such as “believes”, “expects”, “may”, “will”, “could”, “would”, “should”, “intends”, “targets”, “aims”, “projects”, “estimates”, “plans”,
“assumes”, “potentially” or “anticipates” or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy that involve risks and uncertainties. In addition, from time to time, representatives of the Company have made or may make forwardlooking statements orally or in writing. Furthermore, such forward-looking statements may be included in, but are not limited to, press releases or oral statements made by, or with the approval of, an authorized executive officer of the Company. Forward-looking statements include statements
concerning the Company’s plans, objectives, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs, plans or intentions relating to acquisitions, competitive strengths and weaknesses, business strategy and the trends anticipated in the industries and the political and legal environment in which the Company operates and other information that is not historical information.
These forward-looking statements and other statements contained in this Announcement regarding matters that are not historical facts involve predictions. No assurance can be given that such future results will be achieved; actual events or results may differ materially as a result of risks and uncertainties facing the Company. Such risks and uncertainties could cause actual results to vary materially from the future results indicated, expressed or implied in such forward-looking statements. Prospective investors should be aware that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in such forward-looking statements.
When relying on forward-looking statements, prospective investors should carefully consider uncertainties and events. Such forward-looking statements speak only as of the date on which they are made. Accordingly, the Company does not undertake any obligation to update or revise any of them, whether as a result of new information, future events or otherwise other than as required by applicable laws or regulation. The Company does not make any representation, warranty or prediction that the results anticipated by such forward-looking statements will be achieved, and such forward-looking statements represent, in each case, only one of many possible scenarios and should not be viewed as the most likely or standard scenario. Neither the Company nor Beltone may give any assurance or accept any liability for the accuracy of the opinions set forth herein or as to the actual occurrence of any predicted developments. Accordingly, prospective investors should not rely on the forward looking statements in this Announcement and must read the PSN in its entirety.
IBNSINA PHARMA’S MEDICAL CONVOY TO KAFR El-SHEIKH
As a part of Ibnsina Pharma medical convoys campaign in coordination with Misr ElKheir Foundation to inhabitants of rural areas, nation wide that do not receive medical care required.
Accordingly a convoy – specialized in Orthopedics, Pediatrics, Otolaryngology, Urology, and Gynecology – has been sent to Metobus, in El-Rus village, part of Kafr El-Sheikh governorate on the 16th and the 17th of August 2017. Ibnsina Pharma has fully sponsored all medication, x-rays, tests, and surgical operations to all received patients.
On July 26-27, 2017, Ibnsina Pharma in partnership with the Misr ElKheir Foundation dispatched a medical convoy to Fayoum City, where doctors examined and treated more than 500 local patients. The convoy included several doctors specializing in ophthalmic diseases. Ibnsina Pharma employees also volunteered their time to assist doctors, spread awareness about the convoy and share information about disease prevention with local families.
This convoy was the first in a new joint initiative of Ibnsina Pharma and the Misr ElKheir Foundation to dispatch well-equipped medical convoys to rural areas across the country that lack access to quality medical services. The convoys will provide treatment and share information about health and safety practices. Inspired by the success of the company’s Ramadan campaign to provide support to hospitals and medical organizations in need, Ibnsina Pharma looks to the continued expansion of its convoy initiative and to making a real difference in the lives of Egypt’s most vulnerable citizens.
ISO 39001:2012 – Road traffic safety Certificate
